Prodrugs and Targeted Delivery Towards Better ADME Properties
by Rautio, Jarkko; Mannhold, Raimund; Kubinyi, Hugo; Folkers, GerdEdition: 1st
Format: Hardcover
Pub. Date: 2011-01-31
Publisher(s): Wiley-VCH
Other versions by this Author
-
This Item Qualifies for Free Shipping!*
*Excludes marketplace orders.
List Price: $241.86
Buy New
Arriving Soon. Will ship when available.
$230.34
Rent Textbook
Select for Price
Used Textbook
We're Sorry
Sold Out
eTextbook
We're Sorry
Not Available
Summary
This topical reference and handbook addresses the chemistry, pharmacology, toxicology and the patentability of prodrugs, perfectly mirroring the integrated approach prevalent in today's drug design. It summarizes current experiences and strategies for the rational design of prodrugs, beginning at the early stages of the development process, as well as discussing organ- and site-selective prodrugs. Every company employing medicinal chemists will be interested in this practice-oriented overview of a key strategy in modern drug discovery and development.
Author Biography
Jarkko Rautio is professor of pharmaceutical chemistry and head of the multidisciplinary Pharmaceutical and Medicinal Chemistry (PMC) research group at the School of Pharmacy, University of Eastern Finland (formerly University of Kuopio), where he received his PhD in pharmaceutical chemistry in 2000. He subsequently carried out his postdoctoral studies at the University of Maryland, Baltimore, USA, and was a visiting scientist at GlaxoSmithKline, North Carolina, while also co-founding the American Association of Pharmaceutical Scientists (AAPS) Prodrug Focus Group in 2005. Professor Rautio's research focuses on chemistry-based methods, especially prodrugs, to overcome the liabilities of drugs.
Table of Contents
| Prodrug Design and Intellectual Property | |
| Prodrug strategies in drug design | |
| The molecular design of prodrugs by functional group | |
| Increasing lipophilicity for oral drug delivery | |
| Prodrugs Addressing Admet Issues | |
| Modulating solubility through prodrugs for oral and IV drug delivery | |
| Topical and transdermal delivery using prodrugs: mechanism of enhancement | |
| Ocular delivery using prodrugs | |
| Prodrugs designed to target transporters for oral drug delivery | |
| Enzyme-activated prodrug strategies for site-selective drug delivery | |
| Reducing Pre-systemic Drug Metabolism | |
| Codrugs and Soft Drugs | |
| Prodrug approaches for central nervous system delivery | |
| Soft drugs | |
| Improving the use of drug combinations through the codrug approach | |
| The impact of pharmacogenetics on the clinical outcomes of prodrugs | |
| Preclinical and Clinical Consideration for Prodrugs | |
| Intellectual Property Primer on Pharmaceutical Patents with a Special Emphasis on Prodrugs and Metabolites | |
| Pharmacokinetic and biopharmaceutical considerations in prodrug discovery and development | |
| Directed enzyme prodrug therapies | |
| Table of Contents provided by Publisher. All Rights Reserved. |
An electronic version of this book is available through VitalSource.
This book is viewable on PC, Mac, iPhone, iPad, iPod Touch, and most smartphones.
By purchasing, you will be able to view this book online, as well as download it, for the chosen number of days.
Digital License
You are licensing a digital product for a set duration. Durations are set forth in the product description, with "Lifetime" typically meaning five (5) years of online access and permanent download to a supported device. All licenses are non-transferable.
More details can be found here.
A downloadable version of this book is available through the eCampus Reader or compatible Adobe readers.
Applications are available on iOS, Android, PC, Mac, and Windows Mobile platforms.
Please view the compatibility matrix prior to purchase.